Franklin Street Advisors Inc Aeglea Bio Therapeutics, Inc. Transaction History

Franklin Street Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 26, 2022	BUY	$3.5 - $8.42 $7,700 - $18,524	2,200 Added 2.12%	105,800 $503,000
Q1 2021 May 04, 2021	BUY	$6.76 - $8.57 $203,476 - $257,957	30,100 Added 40.95%	103,600 $821,000
Q3 2020 Oct 21, 2020	BUY	$6.51 - $9.33 $152,985 - $219,255	23,500 Added 47.0%	73,500 $521,000
Q2 2020 Aug 06, 2020	BUY	$4.01 - $11.04 $60,150 - $165,600	15,000 Added 42.86%	50,000 $463,000
Q1 2020 Apr 16, 2020	BUY	$3.51 - $8.48 $17,550 - $42,400	5,000 Added 16.67%	35,000 $163,000
Q1 2019 May 14, 2019	BUY	$7.6 - $9.4 $76,000 - $94,000	10,000 Added 50.0%	30,000 $242,000
Q4 2018 Feb 14, 2019	BUY	$6.51 - $10.19 $130,200 - $203,800	20,000 New	20,000 $150,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Franklin Street Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Franklin Street Advisors Inc with notifications on news.